Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Fasting Mimicking Diet (FMD) is a 5-day dietary program developed by L-Nutra Inc, designed to simulate the metabolic effects of water-only fasting while providing essential macronutrients. Marketed as ProLon, the intervention consists of a specific plant-based, low-calorie, low-protein, and low-carbohydrate composition that triggers a state of differential stress resistance. In clinical oncology settings, the FMD is used as an adjunct to chemotherapy to protect healthy cells from treatment-induced toxicity while potentially sensitizing cancer cells to the therapy. This effect is mediated through the reduction of circulating levels of glucose, insulin, and insulin-like growth factor 1 (IGF-1), which shifts normal cells into a protected, maintenance-oriented state while cancer cells, due to their oncogenic mutations, remain vulnerable to chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fasting Mimicking Diet.